However, knockdown of Dio2 using AAV-mediated CRISPR-Cas9 vectors targeted to the MBH conferred no protection from GC-induced hyperphagia or obesity in this setting, providing evidence that other mechanisms mediate the metabolic sequelae resulting from chronic GC treatment. This evidence concerns the gene DIO2 and obesity disorder.